Understanding osteoporosis treatment drugs and jaw bone necrosis

Kim, Jin-Woo; Kim, Sun-Jong

doi:2021.59.11.660

J Korean Dent Assoc > Volume 59(11); 2021 > Article

The Journal of The Korean Dental Association 2021;59(11):660-669.
DOI: https://doi.org/10.22974/jkda.2021.59.11.005 Published online October 31, 2021.

골다공증 치료 약제와 턱뼈괴사증의 이해

이화여자대학교 의과대학 치과학교실 구강악안면외과

Understanding osteoporosis treatment drugs and jaw bone necrosis

Jin-Woo Kim

, Sun-Jong Kim

Department of Oral and Maxillofacial Surgery School of Medicine, Ewha Womans Univesity

Correspondence: Sun-Jong Kim, Tel: 82-2-6986-3401, Fax: 82-2-2650-2754,
Email: sjsj7777@ewha.ac.kr

Abstract

Since the first report of osteonecrosis of the jaw (ONJ) associated with bisphosphonate (BP) administration in 2003, there have been many efforts to establish the pathophysiologic nature of this disease. Given that its pathogenesis is still poorly understood, and the global dependence on BP use and the entry tor aging society, there is a pressing need of related investigations. In this article, the authors aimed to assess the possible ONJinducing drug including BPs, Denosumab, Romosozumab, and etc., and investigate the actual diagnosis and treatment of ONJ.

Key Words: osteonecrosis of the jaw; osteoporosis; bisphosphonates; denosumab; romosozumab